IL114152A - Preparation of stable zinc insulin analog crystals - Google Patents

Preparation of stable zinc insulin analog crystals

Info

Publication number
IL114152A
IL114152A IL11415295A IL11415295A IL114152A IL 114152 A IL114152 A IL 114152A IL 11415295 A IL11415295 A IL 11415295A IL 11415295 A IL11415295 A IL 11415295A IL 114152 A IL114152 A IL 114152A
Authority
IL
Israel
Prior art keywords
preparation
insulin analog
zinc insulin
stable zinc
analog crystals
Prior art date
Application number
IL11415295A
Other languages
English (en)
Other versions
IL114152A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL114152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL114152A0 publication Critical patent/IL114152A0/xx
Publication of IL114152A publication Critical patent/IL114152A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL11415295A 1994-06-16 1995-06-14 Preparation of stable zinc insulin analog crystals IL114152A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (2)

Publication Number Publication Date
IL114152A0 IL114152A0 (en) 1995-10-31
IL114152A true IL114152A (en) 1999-12-31

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11415295A IL114152A (en) 1994-06-16 1995-06-14 Preparation of stable zinc insulin analog crystals

Country Status (29)

Country Link
US (1) US5504188A (en:Method)
EP (1) EP0692489B1 (en:Method)
JP (1) JP3595607B2 (en:Method)
KR (1) KR100369951B1 (en:Method)
CN (1) CN1184234C (en:Method)
AT (1) ATE233278T1 (en:Method)
AU (1) AU697794B2 (en:Method)
BR (1) BR9502798A (en:Method)
CA (1) CA2151563C (en:Method)
CO (1) CO4410205A1 (en:Method)
CZ (1) CZ286066B6 (en:Method)
DE (1) DE69529708T2 (en:Method)
DK (1) DK0692489T3 (en:Method)
ES (1) ES2188637T3 (en:Method)
FI (1) FI952930L (en:Method)
HU (1) HUT73495A (en:Method)
IL (1) IL114152A (en:Method)
IN (1) IN178919B (en:Method)
MY (1) MY130551A (en:Method)
NO (1) NO952334L (en:Method)
NZ (1) NZ272358A (en:Method)
PE (1) PE21896A1 (en:Method)
PL (1) PL180968B1 (en:Method)
RO (1) RO113529B1 (en:Method)
RU (1) RU2156257C2 (en:Method)
SI (1) SI0692489T1 (en:Method)
TW (1) TW379228B (en:Method)
YU (1) YU39595A (en:Method)
ZA (1) ZA954942B (en:Method)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
WO1998042367A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
WO1999024071A1 (en) * 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
CN1210058C (zh) * 1998-10-16 2005-07-13 诺沃挪第克公司 用于肺送递的稳定的浓缩胰岛素制剂
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
HUP0103606A3 (en) * 1998-10-16 2002-05-28 Novo Nordisk As Insulin preparations for pulmonary delivery containing menthol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
NZ526672A (en) * 2001-02-09 2006-10-27 Genentech Inc Process for forming crystalline human insulin-like growth factor-1
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
SI1687019T1 (en) 2003-11-20 2018-04-30 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
UA103758C2 (ru) 2004-07-19 2013-11-25 Биокон Лимитед Конъюгаты олигомеров инсулина, их композиции и применение
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
ES2375929T3 (es) 2005-07-04 2012-03-07 High Point Pharmaceuticals, Llc Antagonistas del receptor histamina h3.
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
PL1951658T3 (pl) 2005-11-17 2013-02-28 Lilly Co Eli Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
CA2645581A1 (en) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles having histamine h3 receptor activity
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
PL2049475T3 (pl) 2006-04-24 2012-08-31 Lilly Co Eli Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1
MX2008014766A (es) 2006-05-29 2009-03-06 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)-piperazi na, sus sales y solvatos y su uso como antagonista del receptor de h3 histamina.
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
MX2009012789A (es) 2007-06-01 2009-12-10 Novo Nordisk As Composiciones farmaceuticas no acuosas estables.
WO2008145728A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
PT2203181T (pt) * 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
CA2744383C (en) 2008-11-21 2017-04-25 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
SG173112A1 (en) 2009-01-28 2011-08-29 Smartcells Inc Conjugate based systems for controlled drug delivery
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2011018745A1 (en) * 2009-08-11 2011-02-17 Biocon Limited Chromatographic processes and purified compounds thereof
WO2012104339A1 (en) 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
US9822158B2 (en) 2013-12-04 2017-11-21 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
PE20230457A1 (es) 2020-03-31 2023-03-10 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales
MX2023005935A (es) 2020-11-19 2023-05-29 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina.
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
PE20251287A1 (es) 2022-05-18 2025-05-14 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina relacionados

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515508A (en:Method) *
BE533298A (en:Method) *
BE533252A (en:Method) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
AU616205B2 (en) * 1988-07-20 1991-10-24 Novo Nordisk A/S Human insulin analogs and preparations containing them
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK0792290T3 (da) * 1993-09-17 2001-10-01 Novo Nordisk As Acyleret insulin
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina

Also Published As

Publication number Publication date
PL180968B1 (pl) 2001-05-31
NO952334L (no) 1995-12-18
AU697794B2 (en) 1998-10-15
KR960000922A (ko) 1996-01-25
IL114152A0 (en) 1995-10-31
CN1184234C (zh) 2005-01-12
US5504188A (en) 1996-04-02
RO113529B1 (ro) 1998-08-28
RU95110107A (ru) 1997-05-10
DK0692489T3 (da) 2003-03-31
ATE233278T1 (de) 2003-03-15
CZ154195A3 (en) 1996-02-14
MY130551A (en) 2007-06-29
JP3595607B2 (ja) 2004-12-02
RU2156257C2 (ru) 2000-09-20
HU9501715D0 (en) 1995-08-28
YU39595A (sh) 1997-08-22
TW379228B (en) 2000-01-11
ZA954942B (en) 1996-12-17
SI0692489T1 (en) 2003-06-30
CO4410205A1 (es) 1997-01-09
NZ272358A (en) 1996-12-20
PL309099A1 (en) 1995-12-27
DE69529708T2 (de) 2003-10-16
NO952334D0 (no) 1995-06-13
FI952930A7 (fi) 1995-12-17
CZ286066B6 (cs) 2000-01-12
FI952930L (fi) 1995-12-17
JPH08169899A (ja) 1996-07-02
HUT73495A (en) 1996-08-28
PE21896A1 (es) 1996-06-15
DE69529708D1 (de) 2003-04-03
EP0692489A1 (en) 1996-01-17
EP0692489B1 (en) 2003-02-26
AU2168195A (en) 1996-01-04
FI952930A0 (fi) 1995-06-14
CA2151563A1 (en) 1995-12-17
CN1128271A (zh) 1996-08-07
IN178919B (en:Method) 1997-07-19
KR100369951B1 (ko) 2003-03-28
BR9502798A (pt) 1996-06-04
ES2188637T3 (es) 2003-07-01
CA2151563C (en) 2007-08-07

Similar Documents

Publication Publication Date Title
ZA954942B (en) Preparation of stable zinc insulin analog crystals
NZ227429A (en) Wound healing composition comprising purified platelet-derived growth factor and purified transforming growth factor alpha and method of use
IE893444L (en) Method for the treatment of periodontal disease
EP0709395A3 (en) Preparation of Stable Insulin Analog Crystals
AU4292585A (en) Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
HUT51596A (en) Process for production of the active substance of the medical composition levodopa
AU1474788A (en) Crystalline human proinsulin and process for its production
AU3812993A (en) Refolding and purification of insulin-like growth factor I
EP0476875A3 (en) Process for the purification and concentration of biologically active materials
AU656349B2 (en) Aramid monofilament with weakly structured skin and process of production thereof
AU7476494A (en) Use of n-methyl-aspartic acid for enhancing growth and altering body composition
AU639107B2 (en) Precursor forms of porcine growth hormone releasing factor and related dna compounds
AU1134688A (en) A composition for the treatment and stimulation of the hair growth
AU4553593A (en) Treatment of diabetes using phosphorylated insulin
HUT48907A (en) Process for production of small peptides linked to 1,4 receptors with immunogene effect and medical preparatives containing these substances
RO102987B1 (ro) Procedeu de purificare a insulinei
Nicholson Glass-ionomers: prospects for the 21 st century
CS237390A2 (en) Method of halohydrogen acids and high-purity diiodohypoiodous acid's production
ZA891863B (en) Novel derivative of human growth hormone
CS8902452A1 (en) Method of porcine insulin's analogue preparation
ATE86497T1 (de) Verwendung von igf-i zur herstellung eines praeparats fuer die behandlung und die verhuetung von nebeneffekten von hyperinsulinemia bei diabetikern behandelt mit insulin.
CS536288A1 (en) Method of oxyhaemoglobin's purified solution preparation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired